X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Urece
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fortress Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabsorption in the kidneys.
Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Urece
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Urica Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2022
Details:
Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.
Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Urece
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fuji Yakuhin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.
Lead Product(s): Dotinurad
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fortress Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 10, 2021
Details:
Under this agreement, Eisai will proceed with the development of dotinurad in China.
Lead Product(s): Dotinurad
Therapeutic Area: Rheumatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
